CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that detailed data from the landmark pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during a late-breaking session, titled “Groundbreaking Trials in Cardiometabolic Therapeutics”, at the American Heart Association (AHA) Scientific Sessions in New Orleans. Ionis previously reported positive topline results from the Phase 3 CORE and
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
